Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annua ...

财务业绩 - 公司2025年前9个月集团总销售额为459亿瑞士法郎，同比增长7% [1] - 制药部门销售额为356亿瑞士法郎，同比增长9% [1] - 诊断部门销售额为103亿瑞士法郎，同比增长1% [1] 业绩展望 - 公司上调2025年全年销售增长指引至中等单位数（CER） [1] - 公司上调2025年全年核心每股收益（Core EPS）增长指引至高单位数至低双位数 [1] 研发管线进展 - 公司将在今年决定或启动十款新分子的三期临床试验 [1] - HER2 TKI即将进入III期临床试验，用于治疗HER2阳性乳腺癌 [1] - Cevostamab已经进入III期临床试验，用于治疗复发/难治性多发性骨髓瘤（R/R MM） [1]